• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial.

作者信息

Cavallari Ilaria, Bhatt Deepak L, Steg Ph Gabriel, Leiter Lawrence A, McGuire Darren K, Mosenzon Ofri, Im Kyungah, Raz Itamar, Braunwald Eugene, Scirica Benjamin M

出版信息

J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.

DOI:10.1016/j.jacc.2021.02.030
PMID:33832610
Abstract
摘要

相似文献

1
Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial.糖尿病患者死亡的原因及危险因素：来自SAVOR-TIMI 53试验的竞争风险分析
J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.
2
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.心力衰竭、沙格列汀和糖尿病：来自 SAVOR-TIMI 53 随机试验的观察结果。
Circulation. 2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.
3
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.在SAVOR-TIMI 53试验中使用沙格列汀的癌症事件发生率。
Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27.
4
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.SAVOR-TIMI 53 试验中老年人参与者使用沙格列汀的疗效和安全性。
Diabetes Care. 2015 Jun;38(6):1145-53. doi: 10.2337/dc14-2868. Epub 2015 Mar 10.
5
Baseline differences in the SAVOR trial.SAVOR试验中的基线差异。
Diabetes Obes Metab. 2015 Dec;17(12):1202. doi: 10.1111/dom.12505. Epub 2015 Jul 8.
6
Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.在SAVOR心血管结局试验中，沙格列汀未显示出心血管死亡、心脏病发作或中风风险增加。
Cardiovasc J Afr. 2013 Aug;24(7):290.
7
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.使用除风险比之外的另一种指标评估2型糖尿病患者使用二肽基肽酶-4抑制剂（沙格列汀、阿格列汀和西他列汀）发生心力衰竭住院风险的情况。
Ann Pharmacother. 2017 Jul;51(7):570-576. doi: 10.1177/1060028017698496. Epub 2017 Mar 1.
8
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.二肽基肽酶-4 抑制剂与退伍军人人群中心力衰竭恶化：一项观察性研究。
Pharmacotherapy. 2018 Mar;38(3):334-340. doi: 10.1002/phar.2085. Epub 2018 Feb 19.
9
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.达格列净/沙格列汀（Qtern）用于2型糖尿病。
Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-56.
10
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?二肽基肽酶IV（DPP-IV）抑制剂会导致心力衰竭吗？
Clin Ther. 2014 Dec 1;36(12):2072-2079. doi: 10.1016/j.clinthera.2014.10.009. Epub 2014 Nov 13.

引用本文的文献

1
Trends in CVD Risk Factors for Youth with Incident Diabetes: SEARCH for Diabetes in Youth.新发糖尿病青年人群心血管疾病危险因素的趋势：青少年糖尿病研究（SEARCH）
Pediatr Diabetes. 2024 Jul 11;2024:5213520. doi: 10.1155/2024/5213520. eCollection 2024.
2
BDH1 overexpression alleviates diabetic cardiomyopathy through inhibiting H3K9bhb-mediated transcriptional activation of LCN2.BDH1过表达通过抑制H3K9bhb介导的LCN2转录激活来减轻糖尿病性心肌病。
Cardiovasc Diabetol. 2025 Feb 28;24(1):101. doi: 10.1186/s12933-025-02646-3.
3
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review.
二肽基肽酶-4抑制剂对糖尿病合并心力衰竭患者的影响：深入综述
Medicina (Kaunas). 2024 Dec 2;60(12):1986. doi: 10.3390/medicina60121986.
4
Causes of Excess Mortality in Diabetes Patients Without Coronary Artery Disease: A Cohort Study Revealing Endocrinologic Contributions.无冠状动脉疾病的糖尿病患者超额死亡率的原因：一项揭示内分泌学作用的队列研究
Clin Epidemiol. 2024 Sep 3;16:571-585. doi: 10.2147/CLEP.S463363. eCollection 2024.
5
Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.基于肠促胰岛素的疗法在临床中治疗心脏代谢疾病的应用：过去、现在与未来。
Med Res Rev. 2025 Jan;45(1):29-65. doi: 10.1002/med.22070. Epub 2024 Aug 14.
6
Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography.采用冠状动脉计算机断层成像术评估动脉粥样硬化和心血管风险。
Eur Heart J. 2024 May 27;45(20):1783-1800. doi: 10.1093/eurheartj/ehae190.
7
Combined obesity- and lipid-related indices are associated with hypogonadism in Chinese male patients with type 2 diabetes: a cross-sectional study.联合肥胖和脂代谢相关指标与中国 2 型糖尿病男性性腺功能减退症的相关性：一项横断面研究。
Front Endocrinol (Lausanne). 2024 Jan 8;14:1319582. doi: 10.3389/fendo.2023.1319582. eCollection 2023.
8
Chinese herbal medicine Shenqi compound for early intervention in patients at high cardiovascular risk of type 2 diabetes mellitus: the protocol of a multicenter, randomized, double-blind, placebo-controlled trial.中药复方参芪复方对2型糖尿病心血管高危患者的早期干预：一项多中心、随机、双盲、安慰剂对照试验方案
Front Cardiovasc Med. 2024 Jan 8;10:1290240. doi: 10.3389/fcvm.2023.1290240. eCollection 2023.
9
A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.一种针对中链酰基辅酶A脱氢酶（MCAD）的基因疗法并不能预防糖尿病诱发的心脏病变。
J Mol Med (Berl). 2024 Jan;102(1):95-111. doi: 10.1007/s00109-023-02397-2. Epub 2023 Nov 21.
10
The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis.基于患者模拟的网络继续医学教育对2型糖尿病实际治疗选择的影响：回顾性病例对照分析
JMIR Med Educ. 2023 Aug 29;9:e48586. doi: 10.2196/48586.